1. Home
  2. DMAC vs PMF Comparison

DMAC vs PMF Comparison

Compare DMAC & PMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • PMF
  • Stock Information
  • Founded
  • DMAC 2000
  • PMF 2001
  • Country
  • DMAC United States
  • PMF United States
  • Employees
  • DMAC N/A
  • PMF N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • PMF Finance/Investors Services
  • Sector
  • DMAC Health Care
  • PMF Finance
  • Exchange
  • DMAC Nasdaq
  • PMF Nasdaq
  • Market Cap
  • DMAC 178.0M
  • PMF 207.9M
  • IPO Year
  • DMAC N/A
  • PMF N/A
  • Fundamental
  • Price
  • DMAC $3.63
  • PMF $7.87
  • Analyst Decision
  • DMAC Strong Buy
  • PMF
  • Analyst Count
  • DMAC 2
  • PMF 0
  • Target Price
  • DMAC $8.00
  • PMF N/A
  • AVG Volume (30 Days)
  • DMAC 110.0K
  • PMF 61.3K
  • Earning Date
  • DMAC 08-06-2025
  • PMF 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • PMF 5.36%
  • EPS Growth
  • DMAC N/A
  • PMF N/A
  • EPS
  • DMAC N/A
  • PMF N/A
  • Revenue
  • DMAC N/A
  • PMF N/A
  • Revenue This Year
  • DMAC N/A
  • PMF N/A
  • Revenue Next Year
  • DMAC N/A
  • PMF N/A
  • P/E Ratio
  • DMAC N/A
  • PMF N/A
  • Revenue Growth
  • DMAC N/A
  • PMF N/A
  • 52 Week Low
  • DMAC $2.14
  • PMF $7.69
  • 52 Week High
  • DMAC $6.82
  • PMF $10.56
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 46.56
  • PMF 35.34
  • Support Level
  • DMAC $4.02
  • PMF $7.81
  • Resistance Level
  • DMAC $4.17
  • PMF $7.90
  • Average True Range (ATR)
  • DMAC 0.25
  • PMF 0.07
  • MACD
  • DMAC -0.04
  • PMF 0.00
  • Stochastic Oscillator
  • DMAC 37.89
  • PMF 13.89

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About PMF PIMCO Municipal Income Fund

PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.

Share on Social Networks: